CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US6867177B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Aug 13, 1999 |
| Grant date | Mar 15, 2005 |
| Priority date | — |
| Expiry date | Aug 13, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method of treating or preventing thrombotic or ischemic disorders in a subject which comprises administering an agent to the subject, wherein the agent inhibits ADP-mediated platelet aggregation by increasing ADP catabolism, and a method for determining whether a compound inhibits platelet aggregation by increasing ADP catabolism so as to treat or prevent thrombotic or ischemic disorders in a subject, comprising: (a) inducing thrombotic or ischemic disorders in an animal, which animal is an animal model for thrombotic or ischemic disorders; (b) measuring the stroke outcome in the animal, (c) measuring platelet deposition and/or fibrin deposition in ischemic tissue, and (d) comparing the stroke outcome in step (b) and the platelet deposition and/or fibrin deposition with that of the animal model in the absence of the compound so as to identify a compound capable of treating or preventing thrombotic or ischemic disorders in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.